| Literature DB >> 30157882 |
Jun Fu1, Ming Ni1, Heng Li2, Xiang Li1, Wei Chai1, Yonggang Zhou1, Libo Hao1, Jiying Chen3.
Abstract
BACKGROUND: Two-stage revision is the standard procedure for periprosthetic knee infection. But when to perform the second-stage is still under debate. We attempt to search the reliable indicators, risk factors, and proper timing for the second-stage revision.Entities:
Keywords: ESR; Intraoperative frozen section; Periprosthetic joint infection; Serum CRP; Total knee revision; Two-stage revision
Mesh:
Year: 2018 PMID: 30157882 PMCID: PMC6114879 DOI: 10.1186/s13018-018-0885-z
Source DB: PubMed Journal: J Orthop Surg Res ISSN: 1749-799X Impact factor: 2.359
Microorganisms detected in 81 periprosthetic knee infection patients
| Organism detected |
| Percentage | |
|---|---|---|---|
| Non methicillin-resistant |
| 12 | 14.8% |
|
| 10 | 12.3% | |
| Coagulase-negative Staphylococcus | 12 | 14.8% | |
|
| 3 | 3.7% | |
| Methicillin-resistant Staphylococcus | MRSE | 9 | 11.1% |
| MRSA | 8 | 9.88% | |
| Fungus |
| 3 | 3.7% |
|
| 5 | 6.17% | |
|
| 1 | 1.23% | |
| Other pathogen | Streptococcus | 4 | 4.94% |
|
| 5 | 6.17% | |
|
| 1 | 1.23% | |
|
| 2 | 2.47% | |
|
| 2 | 2.47% | |
| NTM | 2 | 2.47% | |
|
| 1 | 1.23% | |
|
| 1 | 1.23% |
MRSA methicillin-resistant Staphylococcus aureus, MRSE methicillin-resistant Staphylococcus epidermidis,
NTM non-tuberculosis mycobacterium
Comparison between successful and failed two-stage patients
| Successful two-stage | Failed two-stage | ||
|---|---|---|---|
| Number | 71 | 10 |
|
| Age (years) | 65.14 ± 8.45 | 62.4 ± 6.08 | 0.326 |
| Height(m) | 1.62 ± 0.06 | 1.65 ± 0.09 | 0.147 |
| Weight(kg) | 69.18 ± 11.18 | 72.10 ± 14.76 | 0.461 |
| BMI(kg/m2) | 26.30 ± 3.51 | 26.42 ± 4.82 | 0.919 |
| Pain severity | 0.171 | ||
| I | 42 | 3 | |
| II | 20 | 4 | |
| III | 9 | 3 | |
| Follow-up time (months) | 54.92 ± 27.03 | 43.0 ± 25.30 | 0.191 |
| Spacer detention time (weeks) | 23.97 ± 17.28 | 24.4 ± 11.54 | 0.94 |
| Antibiotic treatment time (weeks) | 7.23 ± 2.14 | 10.20 ± 5.69 | 0.135 |
Information of failed second-stage revisions
| Number | Gender | Age | BMI | Diagnosis | Pathogen | Spacer retention period (weeks) | Failed details | Ending |
|---|---|---|---|---|---|---|---|---|
| 4 | Male | 67 | 22.4 | OA | MRSE | 24 | Sinus recurrence 9 months after spacer implanted | Three spacer implantations, one I&D, infection controlled. |
| 16 | Male | 75 | 17.8 | OA | MRSA | 12 | Sinus recurrence 6 months after prosthesis implanted | Two I&D and insert exchange, fusion |
| 18 | Female | 65 | 27.7 | OA |
| 12 | Reinfection 39 months after new prosthesis implanted | Another one-stage revision, infection controlled |
| 23 | Female | 56 | 26.6 | OA |
| 24 | Infection persist 2 months after spacer implanted | Two spacer implantation, Two I&D and insert exchange, infection controlled |
| 29 | Female | 63 | 23.9 | RA |
| 48 | Infection persist 16 months after spacer implanted | Two spacer implantation, infection controlled |
| 30 | Female | 59 | 28.9 | OA | MRSE | 20 | Reinfection 24 months after prosthesis implanted | Another one-stage revision, infection controlled |
| 32 | Male | 64 | 22.5 | OA | NTM | 24 | Infection persist 9 months after spacer implanted | Three spacer implantations, infection controlled. |
| 35 | Female | 58 | 31.3 | OA |
| 40 | Sinus recurrence 6 months after prosthesis implanted | One I&D and insert exchange, infection controlled |
| 37 | Male | 63 | 34.3 | OA | NTM | 24 | Infection persist 10 months after spacer implanted | Three time spacer implantations, infection controlled |
| 57 | Male | 54 | 28.7 | OA |
| 16 | Reinfection 4 months after prosthesis implanted | One I&D and insert exchange, infection controlled |
MRSA methicillin-resistant Staphylococcus aureus, MRSE methicillin-resistant Staphylococcus epidermidis, NTM non-tuberculosis mycobacterium, I&D irrigation and debridement
Fig. 1ROC curve of intraoperative frozen section, serum CRP, and ES
Diagnostic evaluation of CRP, ESR and Frozen section at re-implantations
| CRP | 40% (13.7–72.6%) | 88.7% (78.5–94.7%) | 33.3% (11.3–64.6%) | 91.3% (81.3–96.4%) | 82.70% | 0.732 | 0.29 |
| ESR | 50% (20.1–80.0%) | 84.5% (73.5–91.6%) | 31.3% (12.1–58.5%) | 92.3% (82.2–97.1%) | 80.20% | 0.688 | 0.35 |
| FS | 90% (54.1–99.5%) | 83.1% (71.9–90.6%) | 42.3% (22.6–65.6%) | 98.3% (89.9–99.9%) | 84.00% | 0.843 | 0.73 |
PPV positive predictive value, NPV negative predictive value, AUC area under the curve
Risk factors for failed two-stage revision
| Variables in the equation | ||||||||
|---|---|---|---|---|---|---|---|---|
| B | SE | Wald | df | Sig. | Exp(B) | 95.0% CI for Exp(B) | ||
| Lower | Upper | |||||||
| Sinus | 2.072 | 0.786 | 6.944 | 1 | 0.008 | 7.942 | 1.701 | 37.093 |
| Antibiotic treatment less than 6 weeks | − 0.596 | 0.978 | 0.372 | 1 | 0.542 | 0.551 | 0.081 | 3.746 |
| Positive CRP | 0.313 | 0.835 | 0.141 | 1 | 0.708 | 1.368 | 0.266 | 7.029 |
| Positive ESR | 1.276 | 0.787 | 2.629 | 1 | 0.105 | 3.582 | 0.766 | 16.753 |
| Positive FS | 1.439 | 0.710 | 4.102 | 1 | 0.043 | 4.215 | 1.047 | 16.959 |
| Atypical pathogen infection | 2.178 | 1.033 | 4.444 | 1 | 0.035 | 8.833 | 1.165 | 66.949 |